BMS looks forward to pivotal readouts for six assets in 2026, ensuring profits after patent expiries for Opdivo and Eliquis.

The trial achieved its primary endpoint, showing a statistically significant reduction in Valsalva LVOT gradient at week 28.

Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer ...

Bristol Myers Squibb is already aiming to launch more than 10 new medicines by 2030. | SAN FRANCISCO—Bristol Myers Squibb is ...

This effort, undertaken by Bristol Myers Squibb and agency partner Real Chemistry, is part of the Champions in Care campaign.

Mature biopharma deals are stealing all the headlines, but Bristol Myers Squibb’s Robert Plenge says the company’s deals with ...

Harald Hampel is recognized as an influential leader in neuroscience, and will bring expertise in Alzheimer's disease to BMS.

Syngene International, a global CRDMO, has extended its long-standing strategic collaboration with Bristol Myers Squibb ...

Bristol Myers Squibb (BMS) has agreed as part of a deal with the US government to provide Eliquis (apixaban) free of charge ...